FPH's Principal Activity is the the company is a designer, manufacturer and marketer ofï¿½products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-27.68%|
|vs ASX 200 (1yr)||-28.14%|
Fisher & Paykel Healthcare Corporation Limited (FPH) is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company's products are sold in over 120 countries worldwide.
Incorporated Following the separation of Fisher & Paykel Industries Limited into two companies: Fisher & Paykel Healthcare Corporation Limited (FPH) and Fisher & Paykel Appliances Holdings Limited (FPA), listed on ASX on 21 Novemeber 2001.
DPS and Yield calculations use the Pay Date.
See Upcoming Dividends for all ASX companies.
|DRP Features||3% Discount|
|Dr Cather Simpson||Non-Executive Director||Jun 2022||
Dr Cather Simpson
Dr Simpson is a professor of physics and chemical sciences at the University of Auckland and a partner at Pacific Channel, an early-stage investment company. She is a director of the International Society for Optics & Photonics (SPIE) and founder/director for Orbis Diagnostics. Dr Simpson also serves on the advisory boards of the Paihau-Robinson Research Institute at Victoria University and the New Zealand Product Accelerator. In 2010, Dr Simpson founded and directed The Photon Factory at the University of Auckland. She is a founder of three high-tech start-up businesses, including Engender Technologies, where she served as Chief Science Officer from 2011 to 2021. She is also a member of the Quality, Safety and Regulatory Committee
|Dr Lisa Margaret McIntyre||Non-Executive Director||Oct 2021||
Dr Lisa Margaret McIntyre
Ms McIntyre is a director of HCF Group, The University of Sydney, Studiosity, and Nanosonics. In addition to her current directorships, she has previously been a director of a range of health entities, including those in healthcare insurance, clinical service delivery and medical research and innovation. She spent 20 years as a senior strategy partner with LEK Consulting providing advice to companies in North America, Asia and Australia.
|Mr Neville Mitchell||Non-Executive Director||Nov 2018||
Mr Neville Mitchell
Mr Mitchell was Chief Financial Officer and Company Secretary of Cochlear Limited between 1995 and 2017. He is a nonexecutive director of Sonic Healthcare and Q'Biotics Group and a former director of The Board of Tax, South East Sydney Local Health District, Osprey Medical and Sirtex Limited. Previously, he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100, and Chairman, Standing Committee (Accounting and Auditing), for the Australian Securities and Investments Commission.
|Ms Philippa (Pip) Mary Greenwood||Non-Executive Director||Jun 2017||
Ms Philippa (Pip) Mary Greenwood
Mr Greenwood is chair of Westpac New Zealand Limited, a director of a2 Milk Company Limited and Vulcan Steel Limited, a current trustee of the Auckland Writers Festival and served as a member of the New Zealand Takeovers Panel from 2007 to 2011. Mr Greenwood was a partner at Russell McVeagh between 2001 and 2019 and served as the firm's Board Chair. She has advised on many high-profile corporate transactions. He is chair of People committee.
|Mr Lewis George Gradon||Chief Executive Officer,Managing Director||Apr 2016||
Mr Lewis George Gradon
Chief Executive Officer,Managing Director
Mr Gradon became Managing Director & Chief Executive Officer in April 2016. Prior to that, he spent 15 years as Senior Vice President - Products & Technology, and six years as General Manager - Research and Development. During his 38-year tenure with Fisher & Paykel Healthcare he has held various engineering positions overseeing the development of our range of products as well the development of our manufacturing, quality, intellectual property, supply chain and clinical research functions.
|Mr Scott Andrew St John||Non-Executive Director,Non-Executive Chairman||Oct 2015||
Mr Scott Andrew St John
Non-Executive Director,Non-Executive Chairman
Mr John is director of ANZ New Zealand Bank Limited, Mercury Limited, the NEXT Foundation and Fonterra Cooperative Group Limited. Scott was Chief Executive Officer of First NZ Capital from 2002 to 2017. He previously served as the Chancellor of the University of Auckland, Chairman of the Securities Industries Association and was a member of the Financial Markets Authority Establishment Board. He is member of risk and people and r Quality, Safety & Regulatory Committee.
|Ms Geraldine Celia McBride||Non-Executive Director||Aug 2013||
Ms Geraldine Celia McBride
Ms McBride has been involved in the technology industry for 30 years and has a wealth of global experience. She has held senior executive roles at SAP AG and Dell Inc, and is a former President of SAP North America. She is a director of Sky Network Television Ltd and the founder and CEO of MyWave.
|Mr Donal Paul O'Dwyer||Non-Executive Director||Dec 2012||
Mr Donal Paul O'Dwyer
Mr O'Dwyer is a director of nib Holdings Limited. From 1996 to 2003, he was with Cordis Cardiology (a division of Johnson & Johnson), initially as its president (Europe) and from 2000 to 2003 as its worldwide president. Prior to joining Cordis, he worked for 12 years with Baxter Healthcare, rising from plant manager in Ireland to president of the Cardiovascular Group, Europe, now Edwards Lifesciences. Previously he served on the boards of Cochlear Limited, Cordis Asset Management and Mesoblast Limited.
|Mr Michael Grenfell Daniell||Non-Executive Director||Nov 2001||
Mr Michael Grenfell Daniell
Mr Daniell was Managing Director and Chief Executive Officer of Fisher & Paykel Healthcare from November 2001 to March 2016. He was General Manager of Fisher & Paykel's medical division from 1990 to 2001 and previously held various technical management and product design roles within the company. Mr Daniell is a director of Cochlear Limited, Tait Limited, the Medical Research Commercialisation Fund, and Chair of Te Titoki Mataora - MedTech Research Translator. He was named a Knight Companion of the New Zealand Order of Merit in June 2021. He is member of risk committee.
|Mr Marcus James Driller||Company Secretary,Vice President - Corporate||N/A|
|Lyndal York||Chief Financial Officer||N/A|
|Paul Shearer||Senior Vice President - Sales & Marketing||N/A|
|Marcus Driller||Vice President - Corporate||N/A|
|Nicola Talbot||Vice President - Human Resources||N/A|
|Nicholas Fourie||Vice President - Information & Communication Technology||N/A|
|Andrew Somervell||Vice President - Products & Technology||N/A|
|Brian Schultz||Vice President - Quality & Regulatory Affairs||N/A|
|Jonti Rhodes||Vice President - Supply Chain, Facilities & Sustainability||N/A|
|Winston Fong||Vice President - Surgical Technologies||N/A|
FPH directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|01/06/22||Scott St John||Buy||+500||$20.92||$10,460||As advised by the company|
|06/12/21||Lisa McIntyre||Buy||+4,400||$32.452||$142,790||As advised by the company|
|16/09/21||Lewis Gradon||Sell||+80,000||$31.215||($2,497,192)||As advised by the company|
|16/09/21||Lewis Gradon||Buy||+32,466||$30.54||$991,511||Conversion of securities|
|16/09/21||Lewis Gradon||Exercise||32,466||$30.54||$991,511||Conversion of securities|
|16/09/21||Lewis Gradon||Buy||+53,038||$30.54||$1,619,780||Exercise of options|
|16/09/21||Lewis Gradon||Exercise||100,313||$30.54||$3,063,559||Exercise of options|
|01/09/21||Lewis Gradon||Issued||25,761||$31.57||$813,274||Issue of securities|
|01/09/21||Lewis Gradon||Issued||73,633||$31.57||$2,324,593||Issue of options|
|04/03/21||Scott St John||Buy||+500||$28.05||$14,025||As advised by the company|
|27/11/20||Scott St John||Buy||+1,500||$32.47||$48,705||As advised by the company|
|10/09/20||Lewis Gradon||Exercise||64,598||$30.85||$1,992,848||Conversion of securities|
|10/09/20||Lewis Gradon||Issued||22,178||$30.85||$684,191||Issue of securities|
|10/09/20||Lewis Gradon||Sell||+135,000||$33.822||($4,565,936)||As advised by the company|
|10/09/20||Lewis Gradon||Issued||64,598||$30.85||$1,992,848||Conversion of securities|
|08/09/20||Lewis Gradon||Issued||73,529||$31.27||$2,299,251||Issue of securities|
|08/09/20||Lewis Gradon||Cancelled||111,364||$31.27||$3,482,352||Cancellation of securities|
|08/09/20||Lewis Gradon||Issued||69,931||$31.27||$2,186,742||Issue of options|
|02/07/20||Michael Daniell||Cancelled||20,000||$32.40||$648,000||Cancellation of securities|
|02/07/20||Michael Daniell||Issued||15,901||$35.281||$561,004||Issue of securities|
|02/07/20||Lewis Gradon||Sell||+136,000||$34.307||($4,665,765)||As advised by the company|
|02/07/20||Lewis Gradon||Issued||86,147||$0.035||$3,039||Issue of securities|
|02/07/20||Lewis Gradon||Cancelled||115,000||$32.40||$3,726,000||Cancellation of securities|
|01/07/20||Scott St John||Buy||+1,500||$34.887||$52,330||As advised by the company|
|01/07/20||Michael Daniell||Sell||+90,000||$34.269||($3,084,209)||As advised by the company|
|03/12/19||Michael Daniell||Issued||13,458||$21.30||$286,655||Issue of securities|
|03/12/19||Michael Daniell||Cancelled||20,000||$20.24||$404,800||Cancellation of securities|
|03/12/19||Scott St John||Buy||+1,000||$21.20||$21,200||As advised by the company|
|02/12/19||Michael Daniell||Sell||+11,000||$22.004||($242,040)||As advised by the company|
|11/09/19||Lewis Gradon||Issued||43,848||$15.84||$694,552||Issue of securities|
|11/09/19||Lewis Gradon||Issued||138,827||$15.84||$2,199,020||Issue of options|
|26/06/19||Scott St John||Buy||+1,500||$15.26||$22,890||As advised by the company|
The current holdings of FPH directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Scott St John||01/06/2022||21,500||N/A||N/A||N/A|
|Philippa (Pip) Greenwood||31/03/2021||N/A||3,800||N/A||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|BlackRock, Inc and related bodies corporate||31/03/2022||37,908,016||6.60|
|Hyperion Asset Management Limited||17/05/2022||28,932,079||5.01|
|Mitsubishi UFJ Financial Group, Inc||26/05/2022||41,852,730||7.25|
|Pinnacle Investment Management Group Limited||12/05/2022||29,363,690||5.09|
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|26-05-22||Mitsubishi UFJ Financial Group, Inc||6,639,641||6.10||7.25|
|17-05-22||Hyperion Asset Management Limited||28,932,079||--||5.01|
|12-05-22||Pinnacle Investment Management Group Limited||29,363,690||--||5.09|
|22-09-21||Mitsubishi UFJ Financial Group, Inc||6,095,588||5.05||6.10|
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
|Year||Closing Price||Last Trade|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.